摘要
目的观察疏血通联合依达拉奉治疗急性脑梗死的疗效和安全性。方法70例急性脑梗死患者随机分为两组:治疗组给予疏血通联合依达拉奉治疗;对照组给予香丹注射液治疗,其他内科常规治疗相同。比较两组治疗前后欧洲脑卒中量表(ESS)和日常生活能力(ADL)评分的变化。结果治疗后治疗组和对照组ESS评分均有改善(P<0.05),但治疗组改善更明显,且与对照组差异有统计学意义(P<0.05);两组ADL水平均较治疗前上升(P<0.01),但治疗组上升更明显,且与对照组差异有统计学意义(P<0.05)。结论疏血通联合依达拉奉治疗急性脑梗死安全有效。
Objective To observe the efficacy and safety of Shuxuetong injection with edaravone in treatment of acute cerebral infarction. Methods 70 patients of acute cerebral infarction were ramdonly divided into two groups：treatment group was done with Shuxuetong injection and edaravone, and the control group was treated by xiangdan. Two groups were treated with routine therapy. ESS and ADL content change in two groups were assessed at different point before treatment and two weeks after treatment. Results The scores of ESS of two groups increased after treatment （ P 〈 0.05 ）, but that in the Shuxuetong group was dramatically increased, showing significantly different from that in the xiangdan group（ P〈0.05 ）. ADL of the two groups improved after treatment（ P〈 0.01 ）, but the increase in the Shuxuetong group was significantly compared to the xiangdan group （ P 〈 0.05 ）. Conclusion Shuxuetong injection combined with edaravone is an effective and safe medicine in treatment of acute cerebral infarction.
出处
《中国基层医药》
CAS
2006年第12期2006-2007,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
疏血通注射液
依达拉奉
脑梗塞
急性
Shuxuetong injection
Edaravone
Cerebral infarction, acute
